menu

Opportunity to join a clinical study

Have you suffered from at least one episode of LPLD/FCS-related pancreatitis? Central Manchester University Hospital is recruiting for an open label volanesorsen study. Participation requires frequent visits and close monitoring. For more details and a summary of inclusion/exclusion criteria please contact ezhil.venukumar@cmft.nhs.uk and/or bethanie.garside@cmft.nhs.uk.
View this article

New Resource

This new resource looks at FCS and is designed to to support both patients and clinicians in areas including FCS diagnosis, symptom management, burden of disease and treatment. It can be found on the Endocrine Society’s public education arm Hormone Health Network.   You can see it here.
View this article

Volanesorsen goes to the EMA for marketing authorisation

“Based on the positive results from the Phase 3 program with volanesorsen, I’m encouraged that for the first time, these patients may have a new therapy that can help them achieve the triglyceride reductions they need to lessen the burden of their disease and decrease their risk for pancreatitis.” Dr. Marcello Arca, Head of the […]
View this article

UK results of IN-FOCUS survey

“FCS impacts most areas of the life of someone who has it and those close to them. It affects everything from what they can eat to their relationships with their friends and family, their employment and their sense of self-worth,” says Jill Prawer, Chair of the LPLD Alliance. “FCS is often misunderstood and misdiagnosed, and […]
View this article
News archive